MODERN APPROACHES TO MANAGING PATIENTS WITH OVARIAN ENDOMETRIOSIS USING PROGESTINS
Main Article Content
Abstract
Aim of the study – to evaluate the efficacy of dydrogesterone use after surgical treatment in patients with ovarian endometriosis.
Study design. Observational study.
Materials and methods. The study included 88 female patients with benign ovarian tumors after surgical treatment. Group A1 included 24 patients with ovarian endometriosis who were prescribed dienogest in the postoperative period. Group A2 included 31 patients with ovarian endometriosis who were prescribed dydrogesterone in the postoperative period. Group B included 33 patients with benign non-endometrioid ovarian tumors who did not receive hormonal therapy. Symptoms, laboratory, and instrumental findings were assessed before the surgery and 6 months postoperatively.
Results. Group A1 demonstrated a significant reduction in the severity of pelvic pain and dysmenorrhea (p < 0,001), as well as normalization of the menstrual cycle (p < 0,001) в сравнении с группой А2. According to ultrasound data, none of the patients developed recurrent adnexal masses 6 months after surgical treatment.
Conclusion. The use of dienogest in a continuous regimen after surgical treatment helps alleviate pain syndrome, normalizes the menstrual cycle in patients with ovarian endometriosis, lowers NSAIDs consumption and prevents the recurrence of endometrioid ovarian cysts.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
1. Horne AW, Missmer SA. Pathophysiology, diagnosis, and management of endometriosis. BMJ. 2022; 379: e070750. doi: 10.1136/bmj-2022-070750
2. Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. Lancet. 2021; 397: 839-852. doi: 10.1016/S0140-6736(21)00389-5
3. Kapoor R, Stratopoulou CA, Dolmans MM. Pathogenesis of endometriosis: New insights into prospective therapies. Int J Mol Sci. 2021;22:11700. doi: 10.3390/ijms222111700
4. Saunders PTK, Horne AW. Endometriosis: Etiology, pathobiology, and therapeutic prospects. Cell. 2021; 184(11): 2807-2824. doi: 10.1016/j.cell.2021.04.041
5. Chen LH, Lo WC, Huang HY, Wu HM. A Lifelong Impact on Endometriosis: Pathophysiology and Pharmacological Treatment. Int J Mol Sci. 2023; 24(8): 7503. doi: 10.3390/ijms24087503
6. Wang PH, Yang ST, Chang WH, Liu CH, Lee FK, Lee WL. Endometriosis: Part I. Basic concept. Taiwan J Obstet Gynecol. 2022; 61(6): 927-934. doi: 10.1016/j.tjog.2022.08.002
7. Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022; 2022(2): hoac009. doi: 10.1093/hropen/hoac009
8. Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C, et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reproductive BioMedicine Online. 2019; 38(2): 249-259. doi: 10.1016/j.rbmo.2018.11.017
9. Ott J, Egarter C, Aguilera A. Dydrogesterone after 60 years: a glance at the safety profile. Gynecol Endocrinol. 2022; 38(4): 279-287. doi: 10.1080/09513590.2021.2016692
10. Orazov MR, Radzinsky VE, Orekhov RE, Tairova MB. Effectiveness of medical therapy for preventing ovarian endometriosis recurrence after surgical treatment. Gynecology, Obstetrics and Perinatology. 2022; 21(3): 53-62. Russian (Оразов М.Р., Радзинский В.Е., Орехов Р.Е., Таирова М.Б. Эффективность профилактики рецидивов после хирургического лечения эндометриоза яичников //Вопросы гинекологии, акушерства и перинатологии. 2022. Т. 21, № 3. С. 53-62.) doi: 10.20953/1726-1678-2022-3-53-62
11. Orazov MR, Radzinsky VE, Orekhov RE. The effectiveness of therapy for endometriosis-associated pelvic pain resistant to surgical treatment. Gynecology. 2021; 23(4): 314-323. Russian (Оразов М.Р., Радзинский В.Е., Орехов Р.Е. Эффективность терапии эндометриоз-ассоциированной тазовой боли, резистентной к хирургическому лечению. Эффективность терапии эндометриоз-ассоциированной тазовой боли, резистентной к хирургическому лечению //Гинекология. 2021. Т. 23, № 4. С. 314-323.) doi: 10.26442/20795696.2021.4.201097
12. Vannuccini S, Clemenza S, Rossi M, Petraglia F. Hormonal treatments for endometriosis: The endocrine background. Rev Endocr Metab Disord. 2022; 23(3): 333-355. doi: 10.1007/s11154-021-09666-w
13. Bezhenar VF, Kruglov SYu, Kuzmina NS, Constandenkova AS, Gramatikova AG, Izorkina VA et al. Analysis of the effectiveness of various methods of managing patients with endometriosis and justification for long-term personalized anti-relapse therapy with dydrogesterone as part of their combination treatment strategy. Russian Journal of Human Reproduction. 2024; 30(2): 102‑111. Russian (Беженарь В.Ф., Круглов С.Ю., Кузьмина Н.С., Констанденкова А.С., Граматикова А.Г., Изоркина В.А. и др. Анализ эффективности различных методов ведения пациенток с эндометриозом и обоснование длительной персонализированной противорецидивной терапии дидрогестероном в рамках стратегии их комбинированного лечения //Проблемы репродукции. 2024. Т. 30, № 2. С. 102-111.) doi: 10.17116/repro202430021102
14. Sukhikh GN, Adamyan LV, Dubrovina SO, Baranov II, Bezhenar VF, Kozachenko AV, et al. Prolonged cyclical and continuous regimens of dydrogesterone are effective for reducing chronic pelvic pain in women with endometriosis: results of the ORCHIDEA study. Obstetrics and Gynecology. News. Opinions. Trainings. 2021; 4(34): 6-18. Russian (Сухих Г.Т., Адамян Л.В., Дубровина С.О., Баранов И.И., Беженарь В.Ф., Козаченко А.В. и др. Пролонгированный циклический и непрерывный режимы применения дидрогестерона эффективны для уменьшения хронической тазовой боли у женщин с эндометриозом: результаты исследования «Орхидея» //Акушерство и гинекология: Новости. Мнения. Обучения. 2021. Т. 9, № 4(34). С. 6-18.) doi: 10.1016/j.fertnstert.2021.07.1194
15. Kwon Y, Kim JH, Chae HD, Lee SR, Kim SH. Clinical Efficacy of Dienogest for Symptomatic Adenomyosis. J Clin Med. 2026; 15(7): 2763. doi: 10.3390/jcm15072763
16. Petraglia F, Hornung D, Seitz C, Faustmann T, Gerlinger C, Luisi S et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet. 2012; 285(1): 167-173. doi: 10.1007/s00404-011-1941-7
17. Khashchenko EP, Alekseeva MN, Pavlovich SV, Uvarova EV. A systematic review of the efficacy and safety of dydrogesterone in the treatment of menstrual disorders in young patients, including early reproductive age. Obstetrics and Gynecology. 2025; (8): 57-68. Russian (Хащенко Е.П., Алексеева М.Н., Павлович С.В., Уварова Е.В. Систематический обзор данных об эффективности и безопасности применения дидрогестерона при лечении нарушений менструального цикла у молодых пациенток, включая период раннего репродуктивного возраста //Акушерство и гинекология. 2025. № 8. С. 57-68.) doi: 10.18565/aig.2025.220
18. Molotkov AS, Yarmolinskaya MI, Tsypurdeeva AA Optimizing treatment approaches for patients with abnormal uterine bleeding. Obstetrics and Gynecology. 2024; (1): 140-152. Russian (Молотков А.С., Ярмолинская М.И., Цыпурдеева А.А. Оптимизация подходов в лечении пациенток с аномальными маточными кровотечениями //Акушерство и гинекология. 2024. № 1. С. 140-152.) doi: 10.18565/aig.2023.301
19. Shi J, Xu Q, Yu S, Zhang T. Perturbations of the endometrial immune microenvironment in endometriosis and adenomyosis: their impact on reproduction and pregnancy. Semin Immunopathol. 2025; 47(1): 16. doi: 10.1007/s00281-025-01040-1
20. Sukhikh GT, Serov VN, Adamyan LV, Baranov II, Bezhenar VF, Gabidullina RI, et al. Algorithms for the management of patients with endometriosis: an agreed position of experts from the Russian Society of Obstetricians and Gynecologists. Obstetrics and Gynecology. 2023; (5):159-176. Russian (Сухих Г.Т., Серов В.Н., Адамян Л.В., Баранов И.И., Беженарь В.Ф., Габидуллина Р.И., и др. Алгоритмы ведения пациенток с эндометриозом: согласованная позиция экспертов Российского общества акушеров-гинекологов //Акушерство и гинекология. 2023. № 5. С. 159-176.) doi: 10.18565/aig.2023.132